ChemicalBook > CAS DataBase List > IPI 145

IPI 145

Product Name
IPI 145
CAS No.
1201438-56-3
Chemical Name
IPI 145
Synonyms
Duvelisib;CS-680;IPI-14;IPI-145;IPI 145;IPI-145, >=98%;IPI-145 INK197;IPI 145 USP/EP/BP;IPI-145 (INK-1197);DUVELISIB (IPI-145)
CBNumber
CB32645143
Molecular Formula
C22H17ClN6O
Formula Weight
416.86
MOL File
1201438-56-3.mol
More
Less

IPI 145 Property

Melting point:
205-206o C
Boiling point:
757.8±60.0 °C(Predicted)
Density 
1.474±0.06 g/cm3(Predicted)
storage temp. 
-20°C
solubility 
Soluble in DMSO (up to at least 25 mg/ml)
form 
White solid.
pka
10.05±0.10(Predicted)
color 
White
Stability:
Stable for 1 year from date of purchase as supplied. Solutions in DMSO may be stored at -20°C for up to 3 months.
More
Less

Hazard and Precautionary Statements (GHS)

Symbol(GHS)
Signal word
Danger
Hazard statements

H360May damage fertility or the unborn child

More
Less

N-Bromosuccinimide Price

Cayman Chemical
Product number
16800
Product name
IPI-145
Purity
≥98%
Packaging
500μg
Price
$68
Updated
2024/03/01
Cayman Chemical
Product number
16800
Product name
IPI-145
Purity
≥98%
Packaging
1mg
Price
$121
Updated
2024/03/01
Cayman Chemical
Product number
16800
Product name
IPI-145
Purity
≥98%
Packaging
5mg
Price
$201
Updated
2024/03/01
Cayman Chemical
Product number
16800
Product name
IPI-145
Purity
≥98%
Packaging
10mg
Price
$335
Updated
2024/03/01
TRC
Product number
I739400
Product name
IPI145
Packaging
50mg
Price
$225
Updated
2021/12/16
More
Less

IPI 145 Chemical Properties,Usage,Production

Description

Duvelisib (1201438-56-3) is a potent and selective (IC50’s: PI3Kα = 1602nM, PI3Kβ = 85nM, PI3Kδ= 2.5nM, PI3Kγ = 27nM) dual PI3Kδ/γ inhibitor.1 It inhibits B and T cell proliferation, blocks neutrophil migration, and inhibits basophil activation. Duvelisib antagonizes B-cell receptor cross-linking activated pro-survival signals in primary chronic lymphocytic leukemia cells.2?Duvelisib also shows preclinical/clinical activity against other hematologic malignancies such as Non-Hodgkins lymphoma, T-cell lymphoma, and others.3,4?Useful clinical agent for the treatment of various blood cancers. Low-dose treatment of T-cell-inflamed tumor models of head and neck cancers with Duvelisib enhanced responses to PD-L1 blockade via suppression of myeloid-derived suppressor cells.5?Higher doses reversed the effect due to suppression of tumor-infiltrating T lymphocytes

Uses

IPI 145 is an 1,2-dihydroisoquinolin-1(2H)-one derivative and has been developed as a modulator of PI3 kinase.

Definition

ChEBI: 8-chloro-2-phenyl-3-[(1S)-1-(7H-purin-6-ylamino)ethyl]-1-isoquinolinone is a member of isoquinolines.

brand name

Copiktra

General Description

Class: lipid kinase; Treatment: CLL, SLL, FL; Other name: INK1197, IPI145; Oral bioavailability = 42%; Elimination half-life = 4.7 h; Protein binding = 98%

Pharmacokinetics

The recommended dose of duvelisib is 25 mg twice daily, much lower than that of idelalisib (150 mg, bid). Duvelisib is rapidly absorbed, with a peak concentration after 1–2 h. Following the administration of 25 mg of duvelisib, the absolute bioavailability in healthy volunteers is 42%. It is eliminated with a short half-life of 4.7 h, thus requiring twice daily administration.

target

PI3Kγ/δ

IC 50

Metabolism

Duvelisib is primarily metabolized by CYP3A4 to give a monooxidation product, IPI-656, which has no pharmacologically relevant activity.

References

1) Winkler?et al.?(2013),?PI3K-δ and PI3K-γ Inhibition by IPI-145 Abrogates Immune Response and Suppresses Activity in Autoimmune and Inflammatory Disease Models;?Chem. Biol.?20?1309 2) Dong?et al.?(2014),?IPI-145 antagonizes intrinsic and extrinsic survival signals in chronic lymphocytic leukemia cells;?Blood?124?3583 3) Flinn?et al.?(2018),?Duvelisib, a novel dual inhibitor of PI3K-δ/γ, is clinically active in advances hematologic malignancies;?Blood?131?877 4) Faia?et al.?(2018),?The phosphoinositide-3 kinase (PI3K)-δ,γ inhibitor, duvelisib, shows preclinical synergy with multiple targeted therapies in hematologic malignancies;?PLoS One?13?e0200725 5) Davis?et al.?(2017),?Anti-PD-L1 Efficacy Can Be Enhanced by Inhibition of Myeloid-Derived Suppressor Cells with a Selective Inhibitor of PI3Kδ/γ;?Cancer Res.?77?2607

IPI 145 Preparation Products And Raw materials

Raw materials

Preparation Products

More
Less

IPI 145 Suppliers

A.J Chemicals
Tel
--
Fax
--
Email
sales@ajchem.in
Country
India
ProdList
6100
Advantage
58
More
Less

View Lastest Price from IPI 145 manufacturers

Zhuozhou Wenxi import and Export Co., Ltd
Product
Duvelisib (IPI-145; INK1197) 1201438-56-3
Price
US $15.00-10.00/KG
Min. Order
1KG
Purity
99%+ HPLC
Supply Ability
Monthly supply of 1 ton
Release date
2021-07-11
Zhuozhou Wenxi import and Export Co., Ltd
Product
Duvelisib (IPI-145; INK1197) 1201438-56-3
Price
US $15.00-10.00/KG
Min. Order
1KG
Purity
99%+ HPLC
Supply Ability
Monthly supply of 1 ton
Release date
2021-07-09
Career Henan Chemical Co
Product
IPI 145 1201438-56-3
Price
US $5.00/KG
Min. Order
1KG
Purity
99%
Supply Ability
1ton
Release date
2019-09-03

1201438-56-3, IPI 145Related Search:


  • IPI145; IPI 145; IPI-145. INK-1197; INK 1197; INK1197;DUVELISIB (IPI-145; INK1197)
  • CS-680
  • 8-chloro-2-phenyl-3-[(1s)-1-(7h-purin-6-ylamino)ethyl]isoquinolin-1-one
  • IPI-145 (Duvelisib, INK1197)
  • IPI-145
  • IPI-145 (INK-1197)
  • IPI-145 INK197
  • 8-Chloro-2-phenyl-3-[(1S)-1-(9H-purin-6-ylamino)ethyl]-1(2H)-isoquinolinone
  • Duvelisib
  • IPI-145, >=98%
  • Duvelisib (IPI-145, INK1197)
  • DUVELISIB (IPI-145)
  • 1(2H)-Isoquinolinone, 8-chloro-2-phenyl-3-[(1S)-1-(9H-purin-6-ylamino)ethyl]-
  • 8-Chloro-2-phenyl-3-[(1S)-1-(9H-purin-6-ylamino)ethyl]-1(2H)-isoquinolinone Duvelisib (IPI-145, INK1197)
  • Duvelisib INK 1197
  • IPI 145
  • IPI 145 (Duvelisib)
  • IPI-145, INK 1197, Duvelisib
  • IPI-145 INK197;DUVELISIB (IPI-145)
  • IPI-14
  • DUVELISIB (IPI-145, INK1197);IPI 145; IPI145
  • Duvelisib, 98%, a novel and selective PI3K δ/γ inhibitor
  • DUVELISIB, 1201438-56-3, DUVELISIB [USAN], SURECN153543, UNII-610V23S0JI, IPI145, CHEMBL3039502, MOLPORT-028-600-025
  • IPI 145 USP/EP/BP
  • IPI-145, INK197,Duvelisib
  • INK-1197,Phosphoinositide 3-kinase,IPI 145,IPI145,inhibit,Duvelisib,PI3K,INK 1197,Inhibitor
  • Dosulepin Impurity 3 (Dosulepin EP Impurity C)
  • 1201438-56-3
  • 201438-56-3
  • reference inhibitors
  • Inhibitors